Share Name Share Symbol Market Type Share ISIN Share Description
Tiziana Life Sciences Plc LSE:TILS London Ordinary Share GB00BKWNZY55 ORD 3P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.00 -1.18% 83.50 527,368 14:37:13
Bid Price Offer Price High Price Low Price Open Price
82.00 85.00 86.50 82.00 86.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -7.85 -5.40 163
Last Trade Time Trade Type Trade Size Trade Price Currency
15:28:11 O 2,774 82.90 GBX

Tiziana Life Sciences (TILS) Latest News

More Tiziana Life Sciences News
Tiziana Life Sciences Investors    Tiziana Life Sciences Takeover Rumours

Tiziana Life Sciences (TILS) Discussions and Chat

Tiziana Life Sciences Forums and Chat

Date Time Title Posts
26/11/202013:52A new cancer research company to watch10,835
21/11/202021:21Short changed!109

Add a New Thread

Tiziana Life Sciences (TILS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Tiziana Life Sciences trades in real-time

Tiziana Life Sciences (TILS) Top Chat Posts

Tiziana Life Sciences Daily Update: Tiziana Life Sciences Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker TILS. The last closing price for Tiziana Life Sciences was 84.50p.
Tiziana Life Sciences Plc has a 4 week average price of 73p and a 12 week average price of 73p.
The 1 year high share price is 304.50p while the 1 year low share price is currently 24.50p.
There are currently 194,612,289 shares in issue and the average daily traded volume is 936,435 shares. The market capitalisation of Tiziana Life Sciences Plc is £163,474,322.76.
tomgreg: The ADS in the US are the equivalent of 2 TILS Shares (their code is TLSA not to be confused with TSLA which is Tesla). An ADS is an American Depository Share traded on Nasdaq and is effectively a US Certificate to show that the holder holds 2 TILS shares within the Crest Depository in the UK. The price of the ADS at close was $2.98. If you divide that by 2 you get $1.49 which is the equivalent US price for one TILS at close, which at the current exchange rate of 1.3241 is the equivalent of £1.12 1/2. It is possible to convert 2 UK shares into 1 ADS (this does incur a fee however) but as the price is so different anyone with enough money could buy TILS here - convert them into ADS and make a whopping profit of 26p per share (minus the costs of the conversion which is not something regular PIs could do but institutions can) by selling them in the US. I'm not suggesting anyone does this as it is difficult, but was looking to highlight the massive price difference. There have been price differences in the past but not so much and not for such a prolonged period. There has been a consistent price difference since 2nd November.
tomgreg: Thank you for your 'explanation' but I am not wrong. The ADS represent the UK shares - The TILS announcement of the 27 Oct clearly states that the demerger date of 30 Oct 2030 is when the demerger is complete and is the same for both 'holders of Tiziana shares and ADRs'. The 'ex-div' or 'ex-entitlement' date for both is therefore the 2nd November 2020 and both assets are trading 'ex' the new shares. The 'record date' is nothing more than a date on which the Registrar (or in the case of the ADS - the ADS issuer - J P Morgan) issue new shares to owners on the 'books' at that date, with any entitlement claims being settled based on the 'ex-date.' Because of the fact few seem to understand how the corporate actions process actually works in practice TILS actually explained this in their announcement of 29 Oct 2020 which said 'Shareholders are reminded that unless the counter-parties specifically agree otherwise, a buyer of the company's ordinary shares ahead of the Ex-Date will assume the benefit to the demerged shares, and a seller ahead of the Ex-Date, would need to pass on the benefit ,even if the seller is recorded as the owner at the Record Date.' This works the same the other way around too and any agreement by the 'counter-parties' alluded to would require a 'Special Ex' or 'Special Cum' dividend bargain condition on the trade. As I said the record date has no bearing on the 'ex-entitlement' status of the shares so this is a genuine 'arbitraging' difference. A similar thing happened on 31st July 2020 when as a holder of the ADS I sold my position at $9.56 (equivalent to £3.70) and bought more of the UK line at £2.75. These discrepancies can and do happen but it is rare for such a difference to persist for what is now three days. This was all I was alluding to.
peverill: Did these ever think that when they stripped out this asset,it would be detrimental to the main businesses asset and share would think they would have a plan to keep the share price from tanking on a daily basis.
onehanded: wow management team are rich lol wait till oct 27th to see the big sell off then. London, New York, 21 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and issued total of 1,750,000 ordinary shares of 3 pence each ("New Ordinary Shares") credited as fully paid; (i) in the case of 1,200,000 New Ordinary Shares at a price of 15 pence per share and; (ii) in the case of 550,000 New Ordinary Shares at a price of 35 pence per share in respect of the exercise of; (i) 1,200,000 options with an exercise price of 15 pence; and (ii) 550,000 options with an exercise price of 35 pence held by Gabriele Cerrone, Executive Chairman of the Company. The aggregate interests of Mr Cerrone in shares and voting rights accordingly increase by 1,750,000 shares to 66,055,668 representing 34.19% of the issued share capital. This is within the 1% increase threshold permitted pursuant to Note 11 to Rule 9 of the UK Takeover Code. Application has been made for the 1,750,000 New Ordinary Shares to be admitted to trading on AIM ("Admission"), and dealings are expected to commence on or around 27 October 2020. The New Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares
jpuff: Perhaps not commenting from a neutral corner, but I don't think a world leading expert in his field at Harvard would put his reputation at stake for a crude ramp of the TILS share price. He came across as genuinely optimistic for the nasally administered foramulab treatment - which has already been demonstrated as safe - thus saving a year testing in these trials. No guarantees obviously but his optimism is encouraging I felt.
gunwalloe: Analyst report suggests significant undervaluation on NASDAQ; on a like for like basis, TILS price target on AIM would be £3.94, NB. this figure excludes the spin-out of Accustem...
pwhite73: heliman2 - "Roger , where is your evidence and research to support this" The evidence is in the timetable in the RNS this morning. 14 October 2020 First Court Hearing in respect of capital reduction 27 October 2020 Second Court Hearing to approve capital reduction 29 October 2020 Capital reduction becomes effective The market cap of TILS must reduce to reflect the demerger of Accustem. So the share price of TILS on or about the 29/10/2020 will certainly collapse. The question is how much will the separate entity Accustem be worth when listed. Well you won't know that until early in 2021 if at all.
hedgehogster: RNS out, excellent news!Tiziana Life Sciences Plc (LSE: TILS, NASDAQ: TLSA) a biotechnology company focussed on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that, following a strategic review of its clinical trial programs and core focus, it intends to demerge its StemPrintER and SPARE genomics-based personalised medicine business into a separate and independent listed company, Accustem Sciences Limited. The proposed demerger, which requires a court-approved reduction of capital to be completed, will allow Accustem to continue the commercialisation efforts of the StemPrintER platform technology as a separate listed company with cash reserves of approximately £1.0 million.The proposed timetable for the demerger is as follows:11:00 a.m. on 2 October 2020 General Meeting to approve the demerger14 October 2020 First Court Hearing in respect of capital reduction27 October 2020 Second Court Hearing to approve capital reduction29 October 2020 Capital reduction becomes effective7:00 a.m. on 30 October 2020 Demerger Record Time30 October 2020 Ex-dividend date30 October 2020 Effective Date of the demergerA circular was sent to shareholders today (the "Circular") providing further information regarding the demerger and seeking approval from its shareholders at a general meeting. Definitions contained in the Circular have the same meanings when used in this announcement. The Circular is available for download from the Company's Rule 26 website.Additional Information regarding the DemergerThe Demerger will be implemented by Tiziana declaring a dividend in specie on the Tiziana Shares equal to the book value (of approximately £3.07m) of Tiziana's shareholding in StemPrintER Sciences, the entity within the Tiziana group which holds all of the assets and intellectual property relating to StemPrintER and SPARE and £1.0 million in cash.The dividend in specie will be satisfied by the transfer by Tiziana to Accustem of the shares in StemPrintER Sciences. In return for this transfer, Accustem will allot Accustem Shares to Tiziana Shareholders who are registered on the Tiziana Share Register at the Demerger Record Time, on the basis of one Accustem Share for each Tiziana Share held by them at that time, save that the number of Accustem Shares to be allotted to the initial subscriber in Accustem (who is, and will at the Demerger Record Time continue to be, a Tiziana Shareholder) will be reduced by the number of Accustem Shares already held by them so that, upon the Demerger becoming effective, each Tiziana Shareholder (including the initial subscriber in Accustem) will hold one Accustem Share for each Tiziana Share held at the Demerger Record Time.It is intended that holders of warrants and options over Tiziana Shares will be granted equivalent instruments in respect of Accustem Shares as a part of the Demerger.It is intended that Accustem will seek admission to the standard segment of the Official List and admission to trading on the London Stock Exchange plc by way of an IPO in late Q4 2020 ("Accustem Admission") and potentially a dual listing on NASDAQ in 2021.Whilst the Accustem Shares will be allotted on the completion of the Demerger, it is unlikely that the process to obtain a standard listing on the Official List and admission to trading on the London Stock Exchange will be complete by the date of completion of the Demerger. Accordingly, no Accustem Shares will be actually issued (or CREST accounts credited or Accustem ADSs issued) until the earlier of (i) Accustem Admission; and (ii) 2 months from the date of the completion of the Demerger. This is to prevent the issue of large numbers of physical share certificates which would then need to be replaced or dematerialised upon Accustem Admission.
volsung: I think we might have a nice rise on Monday morning and the TILS share price might go up a bit too
jaknife: It's stupid to blame the "Shareprophets shorters" for the share price going down. The reason that the share price is going down is simply reversion to the mean - it was worth sweet FA before the concerted ramping/promotion campaign and it's now worth Sweet FA plus the cash that it managed to raise in the pump 'n' dump. If you were suckered into buying the shares as part of the ramp then the only person that you should be "blaming" is yourself for so easily falling for such a blatant ramping scam.
Tiziana Life Sciences share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Tiziana Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201126 15:44:49